QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
NASDAQ:ANGO

AngioDynamics - ANGO Stock Forecast, Price & News

$24.14
+0.69 (+2.94%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$23.78
$24.24
50-Day Range
$17.83
$24.14
52-Week Range
$17.56
$32.00
Volume
125,422 shs
Average Volume
272,459 shs
Market Capitalization
$940.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00

AngioDynamics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
28.4% Upside
$31.00 Price Target
Short Interest
Bearish
3.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.32mentions of AngioDynamics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$112,200 Sold Last Quarter
Proj. Earnings Growth
533.33%
From $0.03 to $0.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

202nd out of 1,108 stocks

Surgical & Medical Instruments Industry

20th out of 112 stocks

ANGO stock logo

About AngioDynamics (NASDAQ:ANGO) Stock

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Raymond James dropped their target price on shares of AngioDynamics from $32.00 to $27.00 and set a "strong-buy" rating on the stock in a research note on Wednesday, July 13th. TheStreet lowered AngioDynamics from a "c-" rating to a "d+" rating in a report on Friday, July 8th. Finally, Canaccord Genuity Group lowered their target price on AngioDynamics from $40.00 to $35.00 in a research note on Wednesday, July 13th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $33.00.

AngioDynamics Stock Performance

Shares of ANGO Stock opened at $23.45 on Wednesday. The firm's 50 day moving average is $20.62 and its 200 day moving average is $21.36. The stock has a market capitalization of $913.85 million, a P/E ratio of -34.48 and a beta of 0.90. AngioDynamics has a 12 month low of $17.56 and a 12 month high of $32.00. The company has a current ratio of 1.93, a quick ratio of 1.24 and a debt-to-equity ratio of 0.06.

AngioDynamics (NASDAQ:ANGO - Get Rating) last posted its quarterly earnings results on Tuesday, July 12th. The medical instruments supplier reported $0.01 EPS for the quarter, hitting analysts' consensus estimates of $0.01. AngioDynamics had a negative return on equity of 0.04% and a negative net margin of 8.40%. The firm had revenue of $87.00 million during the quarter, compared to analyst estimates of $82.91 million. AngioDynamics's revenue was up 13.3% compared to the same quarter last year. On average, sell-side analysts anticipate that AngioDynamics will post 0.03 earnings per share for the current year.

Insider Buying and Selling at AngioDynamics

In other news, SVP Dave Helsel sold 5,000 shares of the stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $22.44, for a total value of $112,200.00. Following the sale, the senior vice president now directly owns 23,822 shares of the company's stock, valued at $534,565.68. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 4.80% of the company's stock.

Receive ANGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.

ANGO Stock News Headlines

AngioDynamics (NASDAQ:ANGO) Issues FY 2023 Earnings Guidance
Raymond James Cuts Price Target On AngioDynamics
See More Headlines
Receive ANGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.

ANGO Company Calendar

Last Earnings
7/12/2022
Today
8/10/2022
Next Earnings (Estimated)
9/29/2022
Fiscal Year End
5/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ANGO
CUSIP
03475V10
Employees
800
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$31.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+28.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-26,550,000.00
Pretax Margin
-9.47%

Debt

Sales & Book Value

Annual Sales
$316.22 million
Cash Flow
$0.76 per share
Book Value
$10.96 per share

Miscellaneous

Free Float
37,099,000
Market Cap
$940.74 million
Optionable
Optionable
Beta
0.90

Social Links















ANGO Stock - Frequently Asked Questions

Should I buy or sell AngioDynamics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ANGO shares.
View ANGO analyst ratings
or view top-rated stocks.

What is AngioDynamics' stock price forecast for 2022?

2 equities research analysts have issued 1-year target prices for AngioDynamics' shares. Their ANGO share price forecasts range from $27.00 to $35.00. On average, they predict the company's share price to reach $31.00 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price.
View analysts price targets for ANGO
or view top-rated stocks among Wall Street analysts.

How have ANGO shares performed in 2022?

AngioDynamics' stock was trading at $27.58 at the beginning of the year. Since then, ANGO stock has decreased by 12.8% and is now trading at $24.04.
View the best growth stocks for 2022 here
.

Are investors shorting AngioDynamics?

AngioDynamics saw a increase in short interest in July. As of July 31st, there was short interest totaling 1,470,000 shares, an increase of 8.9% from the July 15th total of 1,350,000 shares. Based on an average daily trading volume, of 234,100 shares, the short-interest ratio is presently 6.3 days. Approximately 3.9% of the shares of the stock are short sold.
View AngioDynamics' Short Interest
.

When is AngioDynamics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, September 29th 2022.
View our ANGO earnings forecast
.

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) released its earnings results on Tuesday, July, 12th. The medical instruments supplier reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. The medical instruments supplier had revenue of $87 million for the quarter, compared to analyst estimates of $82.91 million. AngioDynamics had a negative net margin of 8.40% and a negative trailing twelve-month return on equity of 0.04%. The company's revenue was up 13.3% on a year-over-year basis.

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics issued an update on its FY 2023 earnings guidance on Tuesday, August, 2nd. The company provided earnings per share guidance of $0.01-$0.06 for the period, compared to the consensus estimate of $0.08. The company issued revenue guidance of $342.00 million-$348.00 million, compared to the consensus revenue estimate of $337.70 million.

What is James C. Clemmer's approval rating as AngioDynamics' CEO?

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (7.53%), Loomis Sayles & Co. L P (3.60%), Frontier Capital Management Co. LLC (0.81%), Allspring Global Investments Holdings LLC (0.43%), Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.21%) and Envestnet Asset Management Inc. (0.13%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends
.

How do I buy shares of AngioDynamics?

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $24.04.

How much money does AngioDynamics make?

AngioDynamics (NASDAQ:ANGO) has a market capitalization of $936.84 million and generates $316.22 million in revenue each year. The medical instruments supplier earns $-26,550,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does AngioDynamics have?

The company employs 800 workers across the globe.

Does AngioDynamics have any subsidiaries?

The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.
Read More

When was AngioDynamics founded?

AngioDynamics was founded in 1988.

How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The official website for the company is www.angiodynamics.com. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at mpolyviou@evcgroup.com, or via fax at 518-795-1401.

This page (NASDAQ:ANGO) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.